| Literature DB >> 26670718 |
Teshale Seboxa1, Wondwossen Amogne1, Workeabeba Abebe2, Tewodros Tsegaye1, Aklilu Azazh3, Workagegnehu Hailu1, Kebede Fufa4, Nils Grude5, Thor-Henrik Henriksen1,6.
Abstract
BACKGROUND: Managing blood stream infection in Africa is hampered by lack of bacteriological support needed for antimicrobial stewardship, and background data needed for empirical treatment. A combined pro- and retrospective approach was used to overcome thresholds in clinical research in Africa.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26670718 PMCID: PMC4682922 DOI: 10.1371/journal.pone.0144944
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of adult patients and the main results for survivors and non-survivors.
| All | Non-survivors N° (%) | Survivors N° (%) | |
|---|---|---|---|
| All | 292 | 44 (15) | 248 (85) |
| Female | 141 | 19 (43) | 122 (49) |
| Median age Years [Range] | 27 [13–98] | 25 [13–70] | 28 [13–98] |
| Median hospital days before blood culture | 2 | 2 | 2 |
| Blood culture growth | 38 | 19 (50) | 19 (50) |
|
| |||
| Positive | 40 | 2 (5) | 38 (95) |
| Negative | 169 | 24 (14) | 145 (86) |
| Unknown | 83 | 18 (22) | 65 (78) |
|
| |||
| Pancytopenia | 89 | 23 (26) | 66 (74) |
| Hgb < 7,0 | 68 | 17 (25) | 51 (75) |
| WBC <1,0 | 21 | 8 (38) | 13 (62) |
| Platelets < 20 | 43 | 19 (44) | 24 (56) |
Odds Ratio for death attributable to bacteriological result, HIV co-infection, pancytopenia, age and AMR.
| Variables | Dead | Alive | Univariate Analysis | Multivariate Analysis |
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
|
| ||||
| Positive blood culture | 19 | 19 | 9.16 (4.29–19.55) | 11.24 (4.88–25.88) |
| HIV positive | 2 | 38 | 5.26 (1.16–29.93) | 3.77 (0.71–20.08) |
| Pancytopenia | 23 | 66 | 3.02 (1.57–5.80) | 3.30 (1.56–6.99) |
| Age | 1.02 (0.99–1.05) | |||
|
| ||||
| HIV positive | 1 | 35 | 5.08 (0.62–41.79) | |
| Pancytopenia | 14 | 63 | 3.35 (1.45–7.78) | 3.12 (1.32–7.39) |
| Age | 1.02 (0.99–1.05) | |||
|
| ||||
| AMR | 17 | 4 | 31.9 (5.1–199.5) | 23.28 (3.3–164.4) |
| HIV positive | 1 | 3 | 9.00 (0.66–122.8) | |
| Pancytopenia | 9 | 3 | 4.80 (1.04–22.10) | 3.65 (0.50–26.59) |
| Age | 1.03 (0.99–1.07) | |||
|
| ||||
| AMR | 11 | 0 | Not done | |
| HIV positive | 1 | 3 | 12.00 (0.5–280.1) | |
| Pancytopenia | 8 | 3 | 3.33 (0.52–21.58) | |
| Age | 1.03 (0.98–1.09) | |||
AMR: Resistance to 3rd. generation Cephalosporins.
Resistance profiles and outcomes for patients with S. aureus sepsis
| Organism | CRO | CTX | Outcome | AmC | CIP | GM | SXT | CC | E | Va |
|---|---|---|---|---|---|---|---|---|---|---|
|
| S | S | Discharged | S | S | S | I | I | I | I |
|
| S | S | Discharged | S | S | S | S | S | S | S |
|
| S | S | Discharged | S | S | S | I | S | S | S |
|
| S | S | Discharged | S | S | S | R | S | S | S |
|
| S | S | Died | S | S | S | S | S | S | S |
|
| I | S | Discharged | S | S | I | R | S | S | S |
|
| R | I | Discharged | S | S | S | R | R | S | S |
CRO, Ceftriaxone; CTX, Cefotaxime; AmC, Amoxicillin + Clavulanic acid; CIP, Ciprofloxacin; GM, Gentamycin; SXT, Sulfamethoxazole + Trimethoprim (Co-trimoxazole); CC, Clindamycin; E, Erythromycin; Va, Vancomycin
Antimicrobial resistance, pancytopenia and outcome for patients with sepsis caused by gram-negative rod-shaped bacteria.
| Organism | CRO | CTX | Pancytopenia | Outcome | AmC | CIP | GM | SXT |
|---|---|---|---|---|---|---|---|---|
|
| R | R | Yes | Died | R | R | R | R |
|
| R | R | Yes | Died | R | R | R | R |
|
| R | R | Yes | Died | R | R | R | R |
|
| R | R | No | Died | R | R | R | R |
|
| R | R | Yes | Died | R | I | R | R |
|
| R | R | Yes | Died | R | I | R | R |
|
| R | R | Yes | Died | I | R | S | R |
|
| R | R | No | Died | I | R | R | |
|
| R | R | Yes | Died | I | R | R | R |
|
| I | I | Yes | Died | S | I | S | |
|
| S | I | No | Died | S | I | S | R |
|
| S | S | Yes | Discharged | S | S | S | S |
|
| S | S | No | Discharged | S | S | S | S |
|
| S | S | No | Died | S | S | S | |
|
| S | S | Yes | Discharged | R | R | R | S |
|
| S | S | No | Discharged | S | R | S | R |
|
| S | S | No | Discharged | I | S | S | S |
|
| S | S | No | Discharged | S | S | S | R |
|
| S | S | No | Discharged | S | S | S | S |
|
| S | S | Yes | Discharged | R | S | R |
CRO, Ceftriaxone; CTX, Cefotaxime; AmC, Amoxicillin + Clavulanic acid; CIP, Ciprofloxacin; GM, Gentamycin; SXT, Sulfamethoxazole + Trimethoprim (Co-trimoxazole); R, Resistance; I, Intermediate susceptibility; S, Susceptibility
Covariation of resistance between ceftazidime and 6 other antibiotics.
Covariation is given as agreement on resistance and susceptibility, respectively, between ceftazidime and one other agent at the time. (100% = full agreement). Four different groups of gram-negative bacteria. Paediatric patients.
| Non-Klebsiella Enterobacteriaceae |
|
|
| All | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| R = 18 | S = 11 | R = 29 | S = 5 | R = 6 | S = 5 | R = 11 | S = 7 | R = 64 | S = 28 |
|
| 83% | 100% | 93% | 20% | 83% | 100% | 64% | 100% | 84% | 85% |
|
| 44% | 100% | 76% | 75% | 83% | 20% | 91% | 72% | 71% | 74% |
|
| 89% | 36% | 88% | 60% | 67% | 80% | 64% | 67% | 82% | 56% |
|
| 94% | 73% | 83% | 60% | 50% | 80% | 80% | 86% | 82% | 75% |
|
| 67% | 100% | 31% | 60% | 0% | 100% | 45% | 100% | 39% | 83% |
|
| 8% | 100% | 4% | 60% | 32% | 50% | 10% | 100% | 10% | 81% |
R, Intermediate susceptibility or resistance; S, Full susceptibility.
Covariation of resistance to third generation cephalosporins, chloramphenicol, co-trimoxazole and gentamicin among gram-negative bacteria, paediatric cohort.
Observed number of isolates expressing resistance to 0–4 antibiotics compared with expected randomly distributed co-resistance (N = 87).
| Frequencies | Expected | Observed (CI) | Relative risk |
|---|---|---|---|
| 0 | 1.8 | 15 (8.7–23.3) | 8.3 |
| 1 | 11.9 | 11 (5.6–18.7) | 0.9 |
| 2 | 29.4 | 8 (3.5–15.1) | 0.3 |
| 3 | 31.5 | 24 (16.1–33.2) | 0.8 |
| 4 | 12.5 | 29 (20.5–38.5) | 2.3 |